The Main Directorate of the State Construction Supervision of the Moscow Region has granted approval for the construction of a sodium heparin manufacturing facility in Voskresensk. A Chinese investor from Shandong, in collaboration with Severny Okean LLC in Russia, has committed an impressive 1.7 billion rubles to the project, which is slated for completion by May 2026. This was reported by the press service of the Main Directorate of State Construction Supervision of the Moscow Region.
The area of the pharmaceutical complex will be 11,000 square meters, and about 250 jobs will be created here. The project is supported by the Construction Assistance Center under the regional government.
The main product will be sodium heparin, an active substance that prevents the formation of blood clots. The production in the Moscow Region is anticipated to fulfill the demand for sodium heparin, a crucial pharmacological substance predominantly supplied by China.
The construction agreement for the plant in Voskresensk was signed at SPIEF-2023 by Andrei Vorobyov, the head of the Moscow Region, and Wang Yongqing, the co-founder of Severny Okean LLC. As stated by a representative of the Chinese investor, other regions were also evaluated as potential locations for the project’s implementation.